92 related articles for article (PubMed ID: 33885953)
1. Hormone replacement therapy in BRCA mutation carriers and risk of ovarian, endometrial, and breast cancer: a systematic review.
Huber D; Seitz S; Kast K; Emons G; Ortmann O
J Cancer Res Clin Oncol; 2021 Jul; 147(7):2035-2045. PubMed ID: 33885953
[TBL] [Abstract][Full Text] [Related]
2. Risk-Reducing Strategies for Ovarian Cancer in
Tschernichovsky R; Goodman A
Oncologist; 2017 Apr; 22(4):450-459. PubMed ID: 28314837
[TBL] [Abstract][Full Text] [Related]
3. Risk factors for endometrial cancer among women with a BRCA1 or BRCA2 mutation: a case control study.
Segev Y; Rosen B; Lubinski J; Gronwald J; Lynch HT; Moller P; Kim-Sing C; Ghadirian P; Karlan B; Eng C; Gilchrist D; Neuhausen SL; Eisen A; Friedman E; Euhus D; Ping S; Narod SA;
Fam Cancer; 2015 Sep; 14(3):383-91. PubMed ID: 25838159
[TBL] [Abstract][Full Text] [Related]
4. Risk of endometrial cancer after RRSO in BRCA 1/2 carriers: a multicentre cohort study.
Pla-Juher H; Pardo M; Izquierdo ÀJ; Darder E; Carbó A; Munté E; Torres-Esquius S; Balmaña J; Lázaro C; Brunet JM; Barretina-Ginesta MP
Clin Transl Oncol; 2024 Apr; 26(4):1033-1037. PubMed ID: 37682500
[TBL] [Abstract][Full Text] [Related]
5. Hormone replacement therapy in gynecological cancer survivors and BRCA mutation carriers: a MITO group survey.
Palaia I; Caruso G; Di Donato V; Turetta C; Savarese A; Perniola G; Gallo R; Giannini A; Salutari V; Bogani G; Tomao F; Giannarelli D; Gentile G; Musella A; Muzii L; Pignata S;
J Gynecol Oncol; 2024 May; 35(3):e70. PubMed ID: 38497108
[TBL] [Abstract][Full Text] [Related]
6. Oophorectomy after menopause and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers.
Kotsopoulos J; Lubinski J; Lynch HT; Kim-Sing C; Neuhausen S; Demsky R; Foulkes WD; Ghadirian P; Tung N; Ainsworth P; Senter L; Karlan B; Eisen A; Eng C; Weitzel J; Gilchrist DM; Blum JL; Zakalik D; Singer C; Fallen T; Ginsburg O; Huzarski T; Sun P; Narod SA
Cancer Epidemiol Biomarkers Prev; 2012 Jul; 21(7):1089-96. PubMed ID: 22564871
[TBL] [Abstract][Full Text] [Related]
7. Risk Factors for Ovarian Cancer by BRCA Status: A Collaborative Case-Only Analysis.
Gersekowski K; Na R; Alsop K; Delahunty R; Goode EL; Cunningham JM; Winham SJ; Pharoah PDP; Song H; Webb PM
Cancer Epidemiol Biomarkers Prev; 2024 Apr; 33(4):586-592. PubMed ID: 38300121
[TBL] [Abstract][Full Text] [Related]
8. Menopausal hormone therapy for BRCA mutation carriers: A case for precision medicine.
Kotsopoulos J; Narod SA
Maturitas; 2024 May; 183():107886. PubMed ID: 37980268
[No Abstract] [Full Text] [Related]
9. BRCA1/2 and Endometrial Cancer Risk: Implications for Management.
Sherman ME; Foulkes WD
J Natl Cancer Inst; 2021 Sep; 113(9):1127-1128. PubMed ID: 33710310
[No Abstract] [Full Text] [Related]
10. Management of patients with BRCA mutation from the point of view of a breast surgeon.
Riis ML
Ann Med Surg (Lond); 2021 May; 65():102311. PubMed ID: 33996049
[TBL] [Abstract][Full Text] [Related]
11. PARP (Poly ADP-Ribose Polymerase) inhibitors for locally advanced or metastatic breast cancer.
Taylor AM; Chan DLH; Tio M; Patil SM; Traina TA; Robson ME; Khasraw M
Cochrane Database Syst Rev; 2021 Apr; 4(4):CD011395. PubMed ID: 33886122
[TBL] [Abstract][Full Text] [Related]
12. BRCA and Breast Cancer-Related High-Penetrance Genes.
Han SA; Kim SW
Adv Exp Med Biol; 2021; 1187():473-490. PubMed ID: 33983595
[TBL] [Abstract][Full Text] [Related]
13. Effect of PARP Inhibitors as Maintenance Treatment on Restricted Mean Survival Time in Platinum-Sensitive Recurrent Ovarian Cancer: A Systematic Review and Meta-analysis.
Kaneko M
Ann Pharmacother; 2022 Jan; 56(1):27-34. PubMed ID: 33926263
[TBL] [Abstract][Full Text] [Related]
14. Characteristics and outcome of BRCA mutated epithelial ovarian cancer patients in Italy: A retrospective multicenter study (MITO 21).
Artioli G; Giannone G; Valabrega G; Maggiorotto F; Genta S; Pignata S; Lorusso D; Cormio G; Scalone S; Nicoletto MO; Greco F; Rossi E; Spagnoletti I; De Giorgi U; Orditura M; Mosconi AM; Kardhashi A; Bogliolo S; Borgato L
Gynecol Oncol; 2021 Jun; 161(3):755-761. PubMed ID: 33888336
[TBL] [Abstract][Full Text] [Related]
15. The Role of Hormonal Replacement Therapy in BRCA Mutated Patients: Lights and Shadows.
Loizzi V; Dellino M; Cerbone M; Arezzo F; Cazzato G; Damiani GR; Pinto V; Silvestris E; Kardhashi A; Cicinelli E; Cascardi E; Cormio G
Int J Mol Sci; 2023 Jan; 24(1):. PubMed ID: 36614207
[TBL] [Abstract][Full Text] [Related]
16. Towards population-based genetic screenings for breast and ovarian cancer: A comprehensive review from economic evaluations to patient perspectives.
Ficarazzi F; Vecchi M; Ferrari M; Pierotti MA
Breast; 2021 Aug; 58():121-129. PubMed ID: 34022715
[TBL] [Abstract][Full Text] [Related]
17. Endometrial Cancer, BRCA1, and BRCA2 in the UK Biobank Cohort.
Lehrer S; Rheinstein PH
Am J Clin Oncol; 2021 Jul; 44(7):299-300. PubMed ID: 34008499
[TBL] [Abstract][Full Text] [Related]
18. High BRCA2 Gene Expression is Associated with Aggressive and Highly Proliferative Breast Cancer.
Satyananda V; Oshi M; Endo I; Takabe K
Ann Surg Oncol; 2021 Nov; 28(12):7356-7365. PubMed ID: 33966140
[TBL] [Abstract][Full Text] [Related]
19. The shifting landscape of genetic alterations separating endometriosis and ovarian endometrioid carcinoma.
Gaia-Oltean AI; Pop LA; Cojocneanu RM; Buse M; Zimta AA; Kubelac P; Irimie A; Coza OF; Roman H; Berindan-Neagoe I
Am J Cancer Res; 2021; 11(4):1754-1769. PubMed ID: 33948387
[TBL] [Abstract][Full Text] [Related]
20. Family planning in carriers of BRCA1 and BRCA2 pathogenic variants.
Haddad JM; Robison K; Beffa L; Laprise J; ScaliaWilbur J; Raker CA; Clark MA; Hofstatter E; Dalela D; Brown A; Bradford L; Toland M; Stuckey A
J Genet Couns; 2021 Dec; 30(6):1570-1581. PubMed ID: 33904624
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
